Drug intelligence / Profile preview

recombinant Bet v 1

Development stage: Phase 3
Lead developer: Allergopharma
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

Recombinant Bet v 1 is a recombinant protein that represents the major birch pollen allergen, Bet v 1. It is developed for specific immunotherapy to treat birch pollen allergy. The drug works by exposing the immune system to the allergen in a controlled manner, aiming to induce tolerance and reduce hypersensitivity reactions in sensitized individuals. It has been shown to induce cutaneous, nasal, and bronchial allergic reactions in vivo and demonstrates IgE binding. Development has been undertaken by companies such as Allergopharma GmbH & Co. KG and Stallergenes Greer.

Brand names: Stalair rBet v 1
Other names: rBet v 1recombinant birch pollen allergenrBet v 1-FV

Targets

IgE (Immunoglobulin E)γδ TCR (T-cell receptor)

Beyond the preview

Go deeper on recombinant Bet v 1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on recombinant Bet v 1.

Explore the full profile